UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

Leukemia, 2012-06, Vol.26 (6), p.1189-1194

2012

Volltextzugriff (PDF)

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase

Leukemia, 2012-05, Vol.26 (5), p.959-962

2012

Volltextzugriff (PDF)

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Leukemia, 2012-10, Vol.26 (10), p.2197-2203

2012

Volltextzugriff (PDF)

CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion

Molecular pathology, 2002-04, Vol.55 (2), p.110-120

2002

Volltextzugriff (PDF)

Activation of the p38 Mitogen-activated Protein Kinase Pathway by Epstein-Barr Virus-encoded Latent Membrane Protein 1 Coregulates Interleukin-6 and Interleukin-8 Production

The Journal of biological chemistry, 1999-06, Vol.274 (23), p.16085-16096

1999

Volltextzugriff (PDF)

CD40 Induces Apoptosis in Carcinoma Cells through Activation of Cytotoxic Ligands of the Tumor Necrosis Factor Superfamily

Molecular and Cellular Biology, 2000-08, Vol.20 (15), p.5503-5515

2000

Volltextzugriff (PDF)

Nuclear factor κB in liver disease

Gut, 1999-08, Vol.45 (2), p.170-171

1999

Volltextzugriff (PDF)

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

The lancet oncology, 2011-09, Vol.12 (9), p.841-851

2011

Volltextzugriff (PDF)

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

Leukemia, 2010-07, Vol.24 (7), p.1299-1301

2010

Volltextzugriff (PDF)

Radiation absorption, growth and yield of cereals

The Journal of agricultural science, 1978-08, Vol.91 (1), p.47-60

1978

Volltextzugriff (PDF)

Effects of drought on grain growth

Nature (London), 1976-01, Vol.264 (5586), p.541-542

1976

Volltextzugriff (PDF)

The development of winter wheat in the field. 1. Relation between apical development and plant morphology within and between seasons

The Journal of agricultural science, 1983-10, Vol.101 (2), p.327-335

1983

Volltextzugriff (PDF)

The effect of nilotinib on major molecular responses (MMR) compared with imatinib in Japanese patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Results from the Japanese subset of ENESTnd

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e17001-e17001

2010

Volltextzugriff (PDF)

The response of field beans ( Vicia faba L.) to irrigation and sowing date. 2. Growth and development in relation to yield

The Journal of agricultural science, 1988-10, Vol.111 (2), p.233-254

1988

Volltextzugriff (PDF)

The development of winter wheat in the field. 2. The control of primordium initiation rate by temperature and photoperiod

The Journal of agricultural science, 1983-10, Vol.101 (2), p.337-344

1983

Volltextzugriff (PDF)

Relations between available and extractable soil water and evapotranspiration from a bean crop

Agricultural water management, 1984-01, Vol.9 (3), p.193-209

1984

Volltextzugriff (PDF)

The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd: 24-month follow-up

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6502-6502

2011

Volltextzugriff (PDF)

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Leukemia, 2012-10, Vol.26 (10), p.2302

2012

Volltextzugriff (PDF)

Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6511-6511

2011

Volltextzugriff (PDF)

Effect of nilotinib on the pharmacokinetics and pharmacodynamics of warfarin

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.7063-7063

2009

Volltextzugriff (PDF)

Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.7053-7053

2009

Volltextzugriff (PDF)

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up: This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue

Leukemia, 2012, Vol.26 (10), p.2197-2203

2012

Volltextzugriff (PDF)

Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.6510-6510

2010

Volltextzugriff (PDF)

Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.6501-6501

2010

Volltextzugriff (PDF)

Erratum: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Leukemia, 2012-10, Vol.26 (10), p.2302-2302

2012

Volltextzugriff (PDF)

1 – 25 von 2.823

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.409)
Mit Volltextzugriff
(2.364)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(1.205)
MEDLINE
(1.053)
Ingenta
(1.024)
Journals@Ovid Ovid Full Text
(917)
NUS Single-Journal Subscriptions
(625)
Elsevier ScienceDirect Journals Collection
(488)
Wiley Online Library
(406)
IngentaConnect Journals
(357)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(339)
Wiley Online Library
(252)
Oxford Journals
(187)
Springer Journals
(175)
JSTOR
(139)
American Physical Society
(121)
Oxford Journals 2020 Medicine
(117)
Nature International Weekly Journal of Science
(113)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(108)
IEEE Xplore Digital Library
(90)
PROLA
(88)
Nexis Uni
(71)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion

Activation of the p38 Mitogen-activated Protein Kinase Pathway by Epstein-Barr Virus-encoded Latent Membrane Protein 1 Coregulates Interleukin-6 and Interleukin-8 Production

CD40 Induces Apoptosis in Carcinoma Cells through Activation of Cytotoxic Ligands of the Tumor Necrosis Factor Superfamily

Nuclear factor κB in liver disease

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

Radiation absorption, growth and yield of cereals

Effects of drought on grain growth

The development of winter wheat in the field. 1. Relation between apical development and plant morphology within and between seasons

The effect of nilotinib on major molecular responses (MMR) compared with imatinib in Japanese patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Results from the Japanese subset of ENESTnd

The response of field beans ( Vicia faba L.) to irrigation and sowing date. 2. Growth and development in relation to yield

The development of winter wheat in the field. 2. The control of primordium initiation rate by temperature and photoperiod

Relations between available and extractable soil water and evapotranspiration from a bean crop

The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd: 24-month follow-up

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up

Effect of nilotinib on the pharmacokinetics and pharmacodynamics of warfarin

Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up: This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue

Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib

Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year

Erratum: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Suchergebnisse filtern